샤페론

378800KOSDAQ기초 의약물질 제조업

51.3 / 100

Reference Date: 2026-06-10

Financial Score18.0 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 42.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Shapieron is a biotech venture specializing in drug development, leveraging its platform targeting GPCR19 to inhibit inflammatory complexes. The company is conducting clinical trials for COVID-19 and Alzheimer's treatments, while expanding into ADC and RPT-based nanobody development. It has established a U.S. subsidiary and demonstrated commercialization capabilities through two technology transfers.

Number of Employees

53people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

1.99Industry Average 1.742.5Point

Higher than industry avg (caution)

ROE

-76.22Industry Average -6.033.5Point

12.6x industry avg (excellent)

Debt Ratio

4.65Industry Average 6.625.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲547.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -70.9% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
샤페론, 글로벌 ADC·이중항체 서밋서 ‘나노맙’ 플랫폼 발표
샤페론의 나노맙 플랫폼 발표로 차세대 항체치료제 사업화 가속화 기대.
Positive
샤페론, 나노맙 기반 차세대 면역항암제 '파필릭시맙' 일본 특허
샤페론의 차세대 면역항암제 파필릭시맙에 대한 일본 특허 확보로 글로벌 시장 진출 강화 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,063Won52-week high 3,11452-week low 1,063

1-month return0.0Point

1m -42.54% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15